COSMOS Pharmaceutical Corporation (3349.T)

Worse than 3088.T's ebitda of 91.30B.

Worse than 3088.T's ebitda margin of 8.76%.

Worse than 3088.T's ebit of 70.29B.

Worse than 3088.T's ebit margin of 6.75%.

Worse than 3088.T's depreciation of 21.01B.

Worse than 3088.T's total cash of 102.45B.

Worse than 3088.T's cash as percentage of revenue of 9.83%.

Worse than 3088.T's accounts payable of 112.45B.

Worse than 3088.T's payables as percentage of revenue of 10.79%.

Worse than 3088.T's weighted average cost of capital (wacc) of 4.93%.

Worse than 3088.T's cost of equity of 4.93%.

Worse than 3088.T's beta of 0.17.

Worse than 3088.T's total debt of 2.21B.

Worse than 3088.T's total equity of 1.17T.

Worse than 3088.T's total capital of 1.17T.

Worse than 3088.T's debt weighting of 0.19%.

Worse than 3088.T's equity weighting of 99.81%.

Worse than 3088.T's ebiat of 46.05B.

Worse than 3088.T's unlevered free cash flow of 54.44B.

Worse than 3088.T's long-term growth rate of 3.00%.

Worse than 3088.T's terminal value of 2.82T.

Worse than 3088.T's enterprise value of 2.45T.

Worse than 3088.T's net debt of -109.55B.

Worse than 3088.T's equity value of 2.56T.

Worse than 3088.T's equity value per share of 6262.49.